Clinical Trials: Novel Approaches in Second-Line ES-SCLC
May 1st 2025Panelists discuss how first-line chemoimmunotherapy has become the standard for extensive-stage small cell lung cancer (ES-SCLC) based on trials such as IMpower133 and CASPIAN, while emerging agents such as DLL3-targeted therapies show promise in the relapsed setting, highlighting the need for personalized approaches and continued clinical trial participation.
Addressing Critical Unmet Needs in ES-SCLC Patient Management
May 1st 2025Panelists discuss how major unmet needs in extensive-stage small cell lung cancer—such as lack of durable responses, limited second-line options, absence of predictive biomarkers, and challenges managing brain metastases—underscore the urgency for more effective therapies and comprehensive supportive care strategies.
Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC
April 24th 2025Panelists discuss how the addition of immune checkpoint inhibitors to first-line chemotherapy has transformed the treatment of extensive-stage small cell lung cancer, improving survival while highlighting ongoing challenges in managing relapse and the need for continued research into novel therapies.
ES-SCLC vs. LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis
April 24th 2025Panelists discuss how distinguishing between limited-stage and extensive-stage small cell lung cancer is essential for guiding treatment strategies, accurately staging disease, and setting appropriate expectations for prognosis and therapeutic outcomes.